Answers are grounded in this paper and cite their sources.
Clinical practice guideline reports diagnostic and treatment strategies in familial hyperaldosteronism, highlighting targeted care for patients with confirmed pathogenic variants.
We describe herein the European Reference Network on Rare Endocrine Conditions clinical practice guideline on diagnosis and management of familial forms of hyperaldosteronism. The guideline panel consisted of 10 experts in primary aldosteronism, endocrine hypertension, paediatric endocrinology, and cardiology as well as a methodologist. A systematic literature search was conducted, and because of the rarity of the condition, most recommendations were based on expert opinion and small patient series. The guideline includes a brief description of the genetics and molecular pathophysiology associated with each condition, the patients to be screened, and how to screen. Diagnostic and treatment approaches for patients with genetically determined diagnosis are presented. The recommendations apply to patients with genetically proven familial hyperaldosteronism and not to families with more than one case of primary aldosteronism without demonstration of a responsible pathogenic variant.
No takes yet. Share an insight, caveat, or question.
Mulatero et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: